SUDEEPPHRMSUDEEPPHRM Forensic Risk Analysis

Pharmaceuticals
Risk ClassStable
Market CapN/A
Primary DriverGrowth Sustainability
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
18 / 100
+4 QoQ
Early Deterioration
Sentinel Insight

Financial profile remains stable for now. Weakness is detected in growth sustainability. No immediate concerns are visible. Risk is gradually increasing.

49.5th %ile (Sector)Accel: +1 Qtrs
Updated2026-06-02
Market View
₹776.9▼0.46%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Growth Sustainability
+9.6 pts
Balance Sheet Stress
+8.0 pts
Final Composite Risk18 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 0 → 18 over 12 quarters.

Expected Direction
⚠ Watch
Primary Deterioration Drivers
  • Inventory Stress
  • Working Capital Expansion
  • Capex Efficiency Stress
What to Watch Next Quarter
  • Working capital efficiency
  • Inventory turnover
  • Operating profit margins

Active Risk Objects (3)

CriticalHigh
Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 2 Years
More Detail
Impact Weight10/15
MomentumAccelerating
Last SignalQ4 FY2026
Working capital expansion detected: Receivable days increased by 3.8%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Inventory Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight15/15
MomentumAccelerating
Last SignalQ4 FY2026
Inventory growth (17.2%) significantly outpaced revenue growth (9.2%).

"Slight build-up in inventory detected. Monitor for slowing sales momentum."

Capex Efficiency Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight8/15
MomentumAccelerating
Last SignalQ2 FY2026
Aggressive Capex (16.6%) amidst slow revenue growth (-74.2%).

"Early signs of earnings quality decay. Profitability is being driven by non-core items."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)2.557.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+48.0+47.0✅ RESILIENT
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹776.9(-0.46%)
1M Divergence+7.53%
1 Week+11.45%
1 Month+9.8%
6 Months+16.09%
1 YearN/A
2 Year+0.36%
3 Year+0.36%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in growth sustainability remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. The current structural trajectory supports a stable risk outlook.

SUDEEPPHRM • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.40%
Trend QualityEarly Base
Phase Progression
Phase Progression Score32.5%
Readiness LabelLow (Early Base Consolidation)
Probability of Advancing40%
CoinTree Momentum
Composite Z-Score+0.8213σ
Improving momentum strength
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#302 of 2716
Top 11.12% in momentum strength
Timeframe Sparklines
1W+11.4%
1M+9.8%
6M+16.1%
Weinstein Indicators
150 DMA₹N/A
200 DMA₹N/A
150 DMA SlopeN/ANeutral
Relative Strength+21.58%Leading
Relative Turnover (RTR)1.0000
ParticipationNeutral

PEER COMPARISON

Ranked comparison against sector peers

Risk profile is broadly in line with the Sector Mean (19).
SUDEEPPHRMSUDEEPPHRM
18 Risk
Sector %ile49th
Delta+4
Active Flags3
Accel+1
Growth Sustainability

Stable

AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

AARTIPHARMAarti Pharmalabs Limited
35 Risk
Sector %ile81th
Delta0
Active Flags18
Accel+0
Earnings Quality

Watch

ALBERTDAVDAlbert David Limited
37 Risk
Sector %ile90th
Delta-8
Active Flags27
Accel+0
Balance Sheet Stress

Watch

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
660th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
0.44th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Inventory Stress

2026

Working Capital Expansion

2026

Working Capital Expansion

2026

Capex Efficiency Stress

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY202667117470148